GMO Financial Gate Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

GMO Financial Gate şirketinin toplam hissedar öz sermayesi ¥5.8B ve toplam borcu ¥2.0B olup, bu da borç-öz sermaye oranını 34.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥14.0B ve ¥8.2B dir. GMO Financial Gate 'in FAVÖK'ü ¥1.5B faiz karşılama oranı 131.6 dur. Şirketin ¥5.1B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

34.5%

Borç/özkaynak oranı

JP¥2.00b

Borç

Faiz karşılama oranı	131.6x
Nakit	JP¥5.07b
Eşitlik	JP¥5.80b
Toplam yükümlülükler	JP¥8.16b
Toplam varlıklar	JP¥13.96b

Son finansal sağlık güncellemeleri

Recent updates

GMO Financial Gate, Inc.'s (TSE:4051) 25% Jump Shows Its Popularity With Investors

Sep 03

With GMO Financial Gate, Inc. (TSE:4051) It Looks Like You'll Get What You Pay For

Jul 17

GMO Financial Gate, Inc.'s (TSE:4051) Earnings Haven't Escaped The Attention Of Investors

Mar 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4051 'nin kısa vadeli varlıkları ( ¥11.6B ) kısa vadeli yükümlülüklerini ( ¥6.1B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4051 şirketinin kısa vadeli varlıkları ( ¥11.6B ) uzun vadeli yükümlülüklerini ( ¥2.1B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4051 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4051 şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 34.5% seviyesine yükseldi.

Borç Kapsamı: 4051 'nin borcu işletme nakit akışı ( 82.2% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 4051 'in borcuna ilişkin faiz ödemeleri EBIT ( 131.6 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

GMO Financial Gate Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

GMO Financial Gate, Inc. Common Stock to Be Deleted from OTC Equity

Recent updates

GMO Financial Gate, Inc. (TSE:4051) announces an Equity Buyback for 74,000 shares, representing 0.89% for ¥500 million.

GMO Financial Gate, Inc. (TSE:4051) announces an Equity Buyback for 74,000 shares, representing 0.89% for ¥500 million.

New major risk - Share price stability

Full year 2024 earnings: EPS exceeds analyst expectations

GMO Financial Gate, Inc., Annual General Meeting, Dec 15, 2024

Upcoming dividend of JP¥52.00 per share

GMO Financial Gate, Inc.'s (TSE:4051) 25% Jump Shows Its Popularity With Investors

GMO Financial Gate, Inc. to Report Fiscal Year 2024 Results on Nov 12, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 22%

Investor sentiment improves as stock rises 17%

With GMO Financial Gate, Inc. (TSE:4051) It Looks Like You'll Get What You Pay For

GMO Financial Gate, Inc. to Report Q3, 2024 Results on Aug 08, 2024

Investor sentiment deteriorates as stock falls 18%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Dividend increased to JP¥52.00

Less than half of directors are independent

GMO Financial Gate, Inc.'s (TSE:4051) Earnings Haven't Escaped The Attention Of Investors

GMO Financial Gate, Inc. to Report Q2, 2024 Results on May 10, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

GMO Financial Gate, Inc. Common Stock to Be Deleted from OTC Equity

GMO Financial Gate, Inc. to Report Q1, 2024 Results on Feb 13, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

GMO Financial Gate, Inc., Annual General Meeting, Dec 17, 2023

New major risk - Share price stability

Upcoming dividend of JP¥39.00 per share at 0.4% yield

GMO Financial Gate, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Price target increased by 13% to JP¥10,808

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GMO Financial Gate, Inc. Provides Dividend Guidance for the Fiscal Year Ending September 30, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

GMO Financial Gate, Inc. Provides Dividend Forecast for the Fiscal Year Ending September 30, 2023

GMO Financial Gate, Inc. to Report Q1, 2023 Results on Feb 13, 2023

Price target decreased to JP¥7,844

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Gmo Financial Gate, Inc. Provides Dividend Forecast for the Fiscal Year Ending September 2023

GMO Financial Gate, Inc., Annual General Meeting, Dec 16, 2022

Upcoming dividend of JP¥57.00 per share

GMO Financial Gate, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus forecasts updated

Price target decreased to JP¥16,583

Now 20% undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued after recent price drop

Now 29% undervalued after recent price drop

GMO Financial Gate, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to JP¥19,750

Less than half of directors are independent

GMO Financial Gate, Inc. to Report Q2, 2022 Results on May 12, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to JP¥26,437

Price target increased to JP¥30,103

Full year 2021 earnings released: EPS JP¥102 (vs JP¥79.61 in FY 2020)

Upcoming dividend of JP¥47.00 per share

Third quarter 2021 earnings released: EPS JP¥24.49 (vs JP¥13.82 in 3Q 2020)

GMO Financial Gate, Inc. to Report Q2, 2021 Results on May 12, 2021

New 90-day high: JP¥25,530

Revenue and earnings beat expectations

New 90-day high: JP¥22,380

GMO Financial Gate, Inc. to Report Q1, 2021 Results on Feb 12, 2021

Full year 2020 earnings released: EPS JP¥79.61

Earnings beat expectations, revenue disappoints

GMO Financial Gate, Inc. to Report Fiscal Year 2020 Results on Nov 11, 2020

GMO Financial Gate, Inc. has completed an IPO in the amount of ¥1.139952 billion.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin